Company intelligence / Profile preview

Paracrine Therapeutics

Durham, North Carolina, United Statesparacrinetherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Paracrine Therapeutics develops proprietary mesenchymal stem cell (MSC) exosome products for regenerative medicine. The company’s approach aims to provide consistent, scalable therapies that avoid the challenges of living cell treatments. It holds an extensive patent portfolio and has been recognized for scientific excellence in the field of MSC exosomes. Specific clinical results or trial data are not disclosed in public sources as of now.

Therapeutic areas: Other
Modalities: Exosome-based therapyStem cell therapy (specifically Mesenchymal Stem Cell exosomes)
Industry: Biotech

Beyond the preview

Go deeper on Paracrine Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Paracrine Therapeutics.

Explore the full profile